Motif BioSciences, Inc.
125 Park Avenue
25th Floor, Suite 2622
New York
New York
10017
United States
Website: https://www.motifbio.com/
Email: info@motifbio.com
About Motif BioSciences, Inc.
52 articles about Motif BioSciences, Inc.
-
Motif Bio Corporate Update - Agreement with Hercules Capital, Inc
1/28/2020
The Company and its wholly owned subsidiary, Motif BioSciences Inc., have entered into a loan Amendment and Release agreement with Hercules Capital Inc., the senior secured lender to Motif Inc, regarding certain actions which fully satisfy the conditions attached to the Company’s previously announced agreement in principle with Hercules
-
Motif Bio plc Announces Voluntary Delisting from the Nasdaq Capital Market
11/26/2019
Motif Bio plc announces that formal notice was given by the Company to Nasdaq on November 25, 2019 of the intention to voluntarily delist the Company’s American Depository Shares and listed warrants from the Nasdaq Capital Market.
-
Motif Bio plc - Result of General Meeting Held on 14 November 2019
11/14/2019
Motif Bio plc of the Company held earlier in New York, all resolutions put to shareholders were duly passed.
-
U.S. Army-funded research project to Evaluate Iclaprim
10/24/2019
Motif Bio plc announced that the Company has signed an agreement with the Walter Reed Army Institute of Research to conduct pre-clinical testing to evaluate novel combinations with iclaprim to improve safety and efficacy administered by a novel enhanced aerosol technology.
-
Motif Bio confirms receipt of FDA meeting minutes
10/15/2019
Motif Bio plc announced that the Company has received the official minutes of the Type B meeting with the U.S. Food & Drug Administration which took place on September 19, 2019..
-
Motif Bio Reports Half-Year 2019 Financial Results, Operational Progress and Proposed Initiatives
9/30/2019
Motif Bio plc announced unaudited financial results for the half year ended June 30, 2019 and reported on its progress year to date.
-
Motif Bio and Hercules Capital Amend Loan and Security Agreement
9/2/2019
Motif Bio plc announces that its lender, Hercules Capital, Inc., has agreed to amend the Company’s loan and security agreement such that the next amortisation date is postponed from September 1 to October 1, 2019.
-
NIH to Evaluate Iclaprim Activity against Listeria
8/20/2019
Motif Bio plc announced that the Company will be utilising NIAID's1 suite of preclinical services through JMI Laboratories to evaluate iclaprim against Listeria monocytogenes, a Gram-positive bacteria causing food-borne, life-threatening infections.
-
Motif Bio Submits Meeting Request and Package to the U.S. FDA for Iclaprim
7/15/2019
Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that it has submitted a meeting request and package to the U.S. Food & Drug Administration (FDA) related to the Company’s lead product candidate, iclaprim.
-
Motif Bio plc AGM Statement
5/22/2019
Motif Bio plc, a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that at the Company’s AGM held earlier the Company provided the following review of key aspects of its business and growth strategy.
-
Motif Bio to Evaluate Orphan Disease Opportunity for Iclaprim in Ophthalmology
5/22/2019
Motif Bio plc announced that the Company has signed an agreement with Otto-von-Guericke University Magdeburg to conduct a study evaluating iclaprim in an in vitro model of ocular toxoplasmosis.
-
Motif Bio plc Notice of Annual General Meeting
4/26/2019
Motif Bio plc announced that its notice of its Annual General Meeting have been posted to shareholders and will shortly be available for download from the Company's website at www.motifbio.com.
-
Motif Bio Announces Appointment of Andrew Powell to Board of Directors
4/26/2019
Motif Bio plc announced the appointment of Andrew Powell, J.D. as Non-executive Director, effective immediately.
-
Motif Bio Presents New Iclaprim Data at ECCMID 2019
4/16/2019
New iclaprim data are being presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2019) in Amsterdam, The Netherlands.
-
Motif Bio to Present Iclaprim Data at ECCMID 2019
4/4/2019
Motif Bio plc, a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced that four iclaprim abstracts have been accepted for presentation at the upcoming 28th European Congress of Clinical Microbiology and Infectious Diseases to be held in Amsterdam, The Netherlands, April 13-16, 2019.
-
Motif Bio Raises £2.7m (US$3.55m)
3/26/2019
The Company expects to be able to provide guidance regarding the path forward for iclaprim upon receipt of the minutes from this meeting, which would typically be within 30 days from the meeting date.
-
Motif Bio Granted Meeting with U.S. FDA regarding Iclaprim
3/20/2019
The meeting is scheduled to take place on May 3, 2019.
-
Over the next two weeks, the U.S. Food and Drug Administration (FDA) has three upcoming decisions. Here’s a look.
-
Motif Bio to participate at upcoming Jefferies London Healthcare Conference
11/1/2018
Motif Bio plc announced today that the Company will participate in the following event
-
Motif Bio Presents New Iclaprim Data at IDWeek on October 4-7, 2018
10/3/2018
Iclaprim safety and efficacy in patients with wound infections in REVIVE Phase 3 trials